Ballentine Partners’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.05M Sell
84,928
-18,852
-18% -$493K 0.03% 216
2026
Q1
$2.91M Buy
103,780
+4,456
+4% +$119K 0.04% 154
2025
Q4
$2.47M Buy
99,324
+9,425
+10% +$238K 0.03% 166
2025
Q3
$2.29M Sell
89,899
-3,329
-4% -$82.2K 0.03% 176
2025
Q2
$2.26M Buy
93,228
+458
+0.5% +$10.7K 0.03% 177
2025
Q1
$2.35M Sell
92,770
-11,718
-11% -$307K 0.04% 165
2024
Q4
$2.77M Sell
104,488
-4,373
-4% -$119K 0.05% 136
2024
Q3
$3.15M Buy
108,861
+1,172
+1% +$34.2K 0.05% 121
2024
Q2
$3.01M Sell
107,689
-7,275
-6% -$200K 0.06% 116
2024
Q1
$3.19M Buy
114,964
+28,589
+33% +$793K 0.06% 107
2023
Q4
$2.49M Sell
86,375
-14,434
-14% -$436K 0.05% 124
2023
Q3
$3.34M Sell
100,809
-6,370
-6% -$225K 0.08% 86
2023
Q2
$3.93M Buy
107,179
+25,837
+32% +$1.01M 0.09% 78
2023
Q1
$3.32M Sell
81,342
-22,888
-22% -$989K 0.08% 89
2022
Q4
$5.34M Buy
104,230
+8,593
+9% +$412K 0.16% 51
2022
Q3
$4.18M Buy
95,637
+3,621
+4% +$176K 0.14% 55
2022
Q2
$4.82M Buy
92,016
+2,774
+3% +$141K 0.17% 51
2022
Q1
$4.62M Sell
89,242
-734
-0.8% -$38.1K 0.14% 52
2021
Q4
$5.31M Sell
89,976
-11,370
-11% -$563K 0.16% 53
2021
Q3
$4.36M Sell
101,346
-1,348
-1% -$59.7K 0.15% 51
2021
Q2
$4.02M Buy
102,694
+264
+0.3% +$10.3K 0.14% 50
2021
Q1
$3.71M Sell
102,430
-16
-0% -$568 0.14% 53
2020
Q4
$3.77M Sell
102,446
-9,246
-8% -$339K 0.15% 49
2020
Q3
$3.89M Sell
111,692
-16,589
-13% -$582K 0.17% 48
2020
Q2
$3.98M Sell
128,281
-13,854
-10% -$471K 0.19% 47
2020
Q1
$4.4M Sell
142,135
-30,120
-17% -$1.03M 0.26% 41
2019
Q4
$6.4M Sell
172,255
-5,655
-3% -$201K 0.29% 37
2019
Q3
$6.07M Sell
177,910
-3,132
-2% -$114K 0.28% 38
2019
Q2
$7.44M Buy
181,042
+115,077
+174% +$4.57M 0.36% 35
2019
Q1
$2.66M Sell
65,965
-3,906
-6% -$156K 0.14% 63
2018
Q4
$2.89M Buy
69,871
+859
+1% +$35.7K 0.17% 52
2018
Q3
$2.88M Buy
69,012
+547
+0.8% +$21.1K 0.15% 58
2018
Q2
$2.36M Buy
68,465
+10,729
+19% +$367K 0.13% 60
2018
Q1
$1.95M Sell
57,736
-5,793
-9% -$199K 0.11% 65
2017
Q4
$2.18M Sell
63,529
-366
-0.6% -$12.5K 0.12% 63
2017
Q3
$2.16M Sell
63,895
-3,277
-5% -$105K 0.12% 63
2017
Q2
$2.11M Buy
67,172
+30,407
+83% +$959K 0.15% 66
2017
Q1
$1.19M Sell
36,765
-2,179
-6% -$68.7K 0.08% 63
2016
Q4
$1.19M Sell
38,944
-34,909
-47% -$1.07M 0.09% 57
2016
Q3
$2.37M Sell
73,853
-8,452
-10% -$283K 0.19% 35
2016
Q2
$2.75M Sell
82,305
-15,082
-15% -$481K 0.23% 35
2016
Q1
$2.74M Buy
97,387
+60,490
+164% +$1.73M 0.24% 36
2015
Q4
$1.13M Buy
36,897
+432
+1% +$13.6K 0.11% 46
2015
Q3
$1.09M Buy
36,465
+877
+2% +$28.1K 0.11% 44
2015
Q2
$1.13M Buy
35,588
+27
+0.1% +$880 0.11% 45
2015
Q1
$1.17M Buy
35,561
+459
+1% +$14.6K 0.12% 42
2014
Q4
$1.04M Sell
35,102
-1,083
-3% -$31.1K 0.12% 47
2014
Q3
$1.01M Sell
36,185
-142
-0.4% -$3.98K 0.12% 45
2014
Q2
$1.02M Sell
36,327
-1,254
-3% -$35.7K 0.12% 45
2014
Q1
$1.15M Buy
37,581
+307
+0.8% +$9.15K 0.13% 39
2013
Q4
$1.08M Buy
37,274
+748
+2% +$21.8K 0.12% 46
2013
Q3
$995K Sell
36,526
-15,763
-30% -$429K 0.12% 46
2013
Q2
$1.39M Buy
+52,289
New +$1.44M 0.19% 34

Other funds holding PFE

Ballentine Partners's PFE Position: Q2 2026 in Review

Ballentine Partners reduced its Pfizer (PFE) stake by 18% in Q2 2026, selling an estimated $493K and leaving 84,928 shares worth $2.05M. The position accounts for 0.03% of the portfolio, ranked #216.

Ballentine Partners first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $7.44M in Q2 2019. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Ballentine Partners held 84,928 shares of Pfizer worth $2.05M as of Q2 2026.
  • Ballentine Partners sold 18,852 Pfizer shares in Q2 2026, an estimated $493K.
  • Pfizer made up 0.03% of Ballentine Partners's portfolio in Q2 2026, its #216 holding.
  • Ballentine Partners first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Ballentine Partners's Pfizer position peaked at $7.44M in Q2 2019.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.